Alkermes' depression treatment fails to get FDA panel backing

November 2, 2018 12:05 AM

54 0

(Reuters) - An advisory panel to the U.S. Food and Drug Administration on Thursday voted against approving Alkermes Plc’s treatment for depression in patients with an inadequate response to standard antidepressant therapies.

The decision comes two days after FDA staff reviewers bit.ly/2QegxPF flagged abuse potential for the opioid-based depression treatment and raised questions on its efficacy.

Also read: Novartis' blood disorder drug gets FDA approval for expanded use

Read more

To category page

Loading...